title: Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
abstract: Cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) have previously been successfully used in immunotherapy of Posttransplant lymphoproliferative disease (PTLD) and Hodgkin's disease. A similar strategy has never been employed in HIV/AIDS patients who also have high risk of developing EBV-associated lymphoma. A total of 5 HIV-infected patients were enrolled to evaluate their EBV-specific T cell responses by Interferon-gamma (IFNgamma) ELISpot assays. Most patients had detectable T cell responses, mainly directed at Epstein-Barr nuclear antigen (EBNA-3). The authors wanted to see whether it was possible to augment magnitude and spectrum of the EBV responses by stimulating patient PBMC with cells presenting autologous EBV antigens. The authors successfully established spontaneously EBV-transformed lymphoblastoid cell lines (EBVh-BCL) and used them for generation of EBV-specific CTL (EBV-CTL). The EBVh-CTL lines established in the present study were not only highly cytotoxic against the autologous virus but also able to secrete IFNgamma detected by ELISpot. The authors are now in the process of generating these lines in a large number and in a clinical grade for adoptive immunotherapy.
authors.affiliation: Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Rama IVRoad, Bangkok 10330, Thailand. fmedphs@md.chula.ac.th
authors.forename: Pokrath
authors.initials: P
authors.lastname: Hansasuta
authors.forename: Patcha
authors.initials: P
authors.lastname: Incomserb
authors.forename: Supranee
authors.initials: S
authors.lastname: Buranapraditkun
authors.forename: Parvapan
authors.initials: P
authors.lastname: Bhattarakosol
mesh_terms: D000328:Adult; D002051:Burkitt Lymphoma / Q000628:therapy*; D020031:Epstein-Barr Virus Infections / Q000517:prevention & control; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D005240:Feasibility Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D019309:Epstein-Barr Virus Nuclear Antigens